Literature DB >> 1723294

Growth factor requirements for the stimulation of germinal center B cells: evidence for an IL-2-dependent pathway of development.

M J Holder1, Y J Liu, T Defrance, L Flores-Romo, I C MacLennan, J Gordon.   

Abstract

Germinal center (GC) B cells readily undergo apoptosis, a tendency which can be suppressed in vitro by immobilized anti-Ig; mAb to CD40 and soluble CD23 (in synergy with IL-1 alpha) also effect rescue of GC cells from programmed cell death. In the present study, the signals which stimulate rescued GC populations to DNA synthesis have been examined and compared to those established for the activation of follicular mantle (FM) B cells. On co-culture with anti-Ig, optimal responses in FM B cells can be achieved with a combination of IL-4 and CD40 antibody; these activities also provided a modest stimulus to GC cells but, for this population, anti-Ig was ineffective at augmenting the response further. Stimulations of GC B cells were enhanced, however, when performed on a support of primary fetal lung fibroblasts; a major influence of stroma was to promote, by direct cell-cell contact, the CD40-dependent survival of GC B cells. FM B cells were relatively independent of such stromal support. In marked contrast to FM cells, GC B cells were found to respond by enhanced DNA synthesis to IL-2 even when quite low concentrations of the factor were present (IC50 = 2 U/ml). Stimulation of GC cells via this pathway was augmented almost 2-fold on the inclusion of anti-Ig whereas neither fibroblasts, IL-4, nor CD40 antibody made any additional contribution to the IL-2-dependent response. The requirements found for stimulating GC cells in vitro are discussed with reference to the signals that this population may encounter in appropriate microenvironments in vivo: the variety of options apparently available could reflect changing priorities at different stages of a developing GC response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723294     DOI: 10.1093/intimm/3.12.1243

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

1.  Locomotor properties of human germinal centre B cells: activation by anti-CD40 and IL-4 allows chemoattraction by anti-immunoglobulin.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

2.  Chemotaxis of human B lymphocytes to anti-IgD.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 3.  B lymphocyte ontogeny and immunoglobulin production.

Authors:  F Hentges
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 4.  Toward an understanding of the molecular mechanisms of physiological cell death.

Authors:  D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

5.  Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts.

Authors:  P Merville; J Déchanet; A Desmoulière; I Durand; O de Bouteiller; P Garrone; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

6.  A Network Model to Describe the Terminal Differentiation of B Cells.

Authors:  Akram Méndez; Luis Mendoza
Journal:  PLoS Comput Biol       Date:  2016-01-11       Impact factor: 4.475

7.  Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.

Authors:  G Cutrona; M Ulivi; F Fais; S Roncella; M Ferrarini
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

8.  Interleukin 13 is a B cell stimulating factor.

Authors:  T Defrance; P Carayon; G Billian; J C Guillemot; A Minty; D Caput; P Ferrara
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

9.  Negative selection of human germinal center B cells by prolonged BCR cross-linking.

Authors:  L Galibert; N Burdin; C Barthélémy; G Meffre; I Durand; E Garcia; P Garrone; F Rousset; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.